Importance of viruses and *Legionella pneumophila* in respiratory exacerbations of young adults with cystic fibrosis

JEFFTHIMIOU, MARGARET E HODSON, P TAYLOR, AG TAYLOR, JC BATTEN

*From the Brompton Hospital and Cardiothoracic Institute and the Central Public Health Laboratory, London*

**ABSTRACT** From January to April 1980 46 young adults with cystic fibrosis were studied for evidence of infection with a wide variety of microorganisms, including viruses and *Legionella pneumophila*. Two groups of patients were investigated: a “deteriorated” group of 24 patients who had experienced an increase in lower respiratory tract symptoms and fall in lung function values in the course of one month before the start of the study and a “stable” group of 22 patients with no such deterioration. All serological tests were repeated at one month and then one year after the beginning of the study. A fourfold rise in titres of antibodies to various viruses, *Mycoplasma pneumoniae*, and *Coxiella burnetii* was obtained in seven (29%) of the deteriorated group but in only one (4.5%) of the stable group (*p* < 0.05). One other patient showed a fourfold rise in *L pneumophila* antibody titre (on the basis of the indirect fluorescent antibody test), which was accompanied by a respiratory illness consistent with legionnaires’ disease. Eight of the 46 patients (17.4%) had demonstrable titres of antibody against *L pneumophila* (1/32 or above).

Bacteria, notably *Pseudomonas aeruginosa*, are assumed to be the most important cause of respiratory exacerbations in patients with cystic fibrosis. The incidence of viral and mycoplasma infections has not been convincingly shown to be higher in patients with cystic fibrosis than in healthy controls, but the consequences of these infections may be more serious. Consequently, it is generally recommended that patients with cystic fibrosis should be immunised against influenza. Despite extensive investigation, however, some 20% of the respiratory exacerbations in these patients may not be associated with any of the common bacteria or viruses. *Legionella pneumophila*, which has a predilection for patients who are debilitated or suffer from chronic lung disease, is a plausible cause of respiratory deterioration in patients with cystic fibrosis. Apart from a preliminary report from Philadelphia in which a stable population of patients with cystic fibrosis was screened for antibodies against *L pneumophila* as a single epidemiological observation, almost nothing is known of the role of this bacterium in cystic fibrosis. The present study was undertaken to investigate the role of viruses and *L pneumophila* in the acute respiratory exacerbations of young adults with cystic fibrosis.

**Patients and methods**

Forty six patients with cystic fibrosis (25 male, 21 female) with a mean age of 22.2 years (range 16–41 years) were studied for evidence of infection with viruses, *L pneumophila, Mycoplasma pneumoniae, Coxiella burnetii*, and *Chlamydia psittaci*, as well as for the usual bacterial pathogens. Both culture and serological methods were used.

The patients were the first 46 seen in the cystic fibrosis clinic at the Brompton Hospital from January to April 1980. All patients had had a uniform pattern of attendance at the clinic (monthly or more frequent) before the initial study visit. The patients were classified as either “deteriorated” or “stable.” The deteriorated group consisted of 24 patients in whom an increase in cough, sputum production or breathlessness was accompanied by an FEV1, at least 15% less than the value obtained at a preliminary visit one month before. The stable group consisted of 22 patients who were both clinically stable and had steady lung function values. A control group of...
30 healthy hospital volunteers was also studied. Each group had similar numbers of men and women and similar age distributions. In all patients the diagnosis of cystic fibrosis had been established clinically and confirmed by the finding of a raised sweat sodium concentration (over 70 mmol (mEq)/l).

Nose and throat swabs and samples of sputum and serum were collected from the patients and controls at the initial visit. Antibodies against influenza A and B and parainfluenza (serotype 1) viruses, adenovirus, respiratory syncytial virus, varicella-zoster virus, M pneumoniae, Chlamydia psittaci, and Coxiella burnetii were detected by complement fixation. An indirect fluorescent antibody test, using formalised yolk sac antigens, was used to detect antibodies to L pneumophila serogroups 1–6. All serological tests were repeated one month and again one year after the patient’s initial visit.

Three cell lines (primary monkey kidney, Hep-2 cells, human embryonic lung fibroblasts) were used for isolation of the previously mentioned viruses and rhinovirus. The relationship between the presence of demonstrable titres of antibody against L pneumophila and the use of aerosol treatment, the number of hospital admissions in the preceding year, and the patient’s lung function was examined. Lung function had been assessed at a preliminary routine outpatient visit one month before the start of the study and the tests were repeated subsequently at the initial visit when the patients were allocated to the “stable” or “deteriorated” groups.

The binomial, median, and χ² tests and Fisher’s exact test were used for statistical analysis.

Results

A fourfold rise in complement fixing antibody titre was observed in paired sera from seven (29.2%) of the 24 patients in the “deteriorated” group and from one (4.5%) of the 22 patients in the “stable” group, but in none of the healthy control group. Sequential antibody titres, from the time of the initial visit to the end of the study one year later, for the patients with positive results are shown in table 1. The agents responsible for these positive serological results were respiratory syncytial virus in two patients, influenza A virus, adenovirus (serotype 7), varicella-zoster virus, M pneumoniae, and C burnetii in the deteriorated group and an adenovirus (serotype 7) in the stable group. The patient with serological evidence of varicella-zoster infection had a rash and illness consistent with chickenpox. Only the two adenovirus and the varicella-zoster infections were confirmed by isolation of the virus in the three cell lines used. This low isolation rate probably reflects the low level of infection in the community at the time of the study. All of the infections in the deteriorated group were accompanied by acute exacerbations of lower respiratory tract disease.

The result of the indirect fluorescent antibody test for L pneumophila are shown in tables 2 and 3. One patient, in the deteriorated group (case 9), had a fourfold rise in antibody titre against L pneumophila (serogroup 1) from <1/16 to 1/64. This was accompanied by clinical deterioration responsive to treatment with erythromycin. In two other patients with L pneumophila antibody titres of 1/32 in February 1980 (cases 10 and 11) considerably raised titres of 1/128 had been present in a pilot study carried out one year before the present study. In all, a total of eight patients (17.4%) had demonstrable titres of antibody against L pneumophila of 1/32 or more in one or both of the original paired sera (seven in the deteriorated group and one in the stable group). Six were male and two female and all had Pseudomonas aeruginosa in the sputum. All had moderate to severe disease with airflow limitation but only one patient was receiving corticosteroid treatment. None of the healthy control group had antibody titres of more than 1/15. At follow up one year later the antibody titres in these eight patients had fallen to 1/16 or less. All L pneumophila serogroups, except serogroups 3 and 5, were represented in the positive results. Two of the patients with L pneumophila antibody titres of 1/32 (both to serogroup 4) also had raised antibody titres to a virus, respiratory syncytial virus in one patient and influenza A virus in the other.

Significantly fewer patients in the stable group had serological evidence of non-bacterial infection (p < 0.05) but there was no significant difference between the stable and deteriorated groups in terms of their principal sputum pathogens—namely P aeruginosa, Haemophilus influenzae, and Staphylococcus pyogenes (table 4). Furthermore, the patients with serological evidence of infection with M pneumoniae and Coxiella burnetii and those with L pneumophila antibody titres of 1/32 or more were similar to the rest of the patients in terms of the principal bacterial pathogens in their sputum. No significant association was found between demonstrable titres of antibody against L pneumophila and the use of aerosol treatment, the number of hospital admissions in the preceding year, or FEV₁ and FVC.

Analysis of the data on the stable and deteriorated groups showed no significant differences in sputum bacteria or respiratory symptoms before the beginning of the study. The mean number of hospital admissions was 1·6 in the deteriorated group in the year preceding the study compared with 0·6 in the stable group (p < 0·05). The mean (SEM) FEV₁ was 1·32 (0·17) l in the deteriorated group com-
Table 1  Sequential complement fixing antibody titres in cystic fibrosis patients with positive serological results

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Group</th>
<th>Organism</th>
<th>Initial visit</th>
<th>Antibody titre at initial visit</th>
<th>1 m later</th>
<th>1 y later</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Deteriorated</td>
<td>Respiratory syncytial virus</td>
<td>Jan 1980</td>
<td>&lt;1/20</td>
<td>1/320</td>
<td>&lt;1/20</td>
</tr>
<tr>
<td>2</td>
<td>Deteriorated</td>
<td>Influenza A virus</td>
<td>Jan 1980</td>
<td>&lt;1/20</td>
<td>1/160</td>
<td>&lt;1/20</td>
</tr>
<tr>
<td>3</td>
<td>Deteriorated</td>
<td>Respiratory syncytial virus</td>
<td>Feb 1980</td>
<td>&lt;1/20</td>
<td>1/160</td>
<td>&lt;1/20</td>
</tr>
<tr>
<td>4</td>
<td>Deteriorated</td>
<td>Adenovirus</td>
<td>Feb 1980</td>
<td>&lt;1/20</td>
<td>1/160</td>
<td>&lt;1/20</td>
</tr>
<tr>
<td>5</td>
<td>Stable</td>
<td>Adenovirus</td>
<td>Mar 1980</td>
<td>1/40</td>
<td>1/640</td>
<td>1/40</td>
</tr>
<tr>
<td>6</td>
<td>Deteriorated</td>
<td>Coxiella burnetii</td>
<td>Apr 1980</td>
<td>&lt;1/20</td>
<td>1/160</td>
<td>&lt;1/20</td>
</tr>
<tr>
<td>7</td>
<td>Deteriorated</td>
<td>Varicella-zoster virus</td>
<td>Apr 1980</td>
<td>&lt;1/20</td>
<td>1/160</td>
<td>&lt;1/20</td>
</tr>
<tr>
<td>8</td>
<td>Deteriorated</td>
<td>Mycoplasma pneumoniae</td>
<td>Apr 1980</td>
<td>&lt;1/20</td>
<td>1/160</td>
<td>&lt;1/20</td>
</tr>
</tbody>
</table>

Discussion

Serological evidence of viral, mycoplasma, and coxiella ("non-bacterial") infections was obtained in 29% of patients with acute exacerbations of their respiratory disease. The proportions have ranged from 20% to 39% in previous studies, although in none of these was a "stable" group of patients also examined or tests for rhinoviruses, known to be important causes of respiratory illness, carried out. Significantly fewer patients in our stable group had serological evidence of non-bacterial infection, suggesting that when a patient with cystic fibrosis contracts a virus, mycoplasma, or coxiella infection significant respiratory deterioration is likely to follow. As the deteriorated group, however, had significantly poorer lung function even before their initial visit the possibility arises that the more severely affected patients were more susceptible to such non-bacterial infections.

Infected with these organisms seems to have been directly responsible for the acute respiratory exacerbations to which they were at least temporally related. This is not surprising as it is known that some non-bacterial agents—for example, respiratory syncytial virus and Mycoplasma pneumoniae, may cause severe lower respiratory tract infections, especially during childhood. Alternatively, the viral, mycoplasma, and coxiella infections may have damaged the respiratory epithelium or other pulmonary defence mechanisms, thereby potentiating the pathogenicity of the bacteria, particularly P aeruginosa, already present in the lungs.

Demonstrable titres of L pneumophila antibody (≥ 1/32) were obtained in 17.4% of the patients with cystic fibrosis, again significantly more of these being in the deteriorated group (p < 0.05). This incidence compares with 22% from a study in Philadelphia, where a group of stable patients with cystic fibrosis was screened for antibodies against L pneumophila as a single epidemiological observation. A formalised yolk sac antigen was not used in

Table 2  Sequential Legionella pneumophila antibody titres in patients with cystic fibrosis having titres of 1/32 or more (indirect fluorescent antibody test)

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Group</th>
<th>L. pneumophila serogroup</th>
<th>Antibody titre at initial visit</th>
<th>1 m later</th>
<th>1 y later</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>At initial visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Deteriorated</td>
<td>4</td>
<td>1/32</td>
<td>1/32</td>
<td>&lt;1/16</td>
</tr>
<tr>
<td>3</td>
<td>Deteriorated</td>
<td>1</td>
<td>1/32</td>
<td>1/32</td>
<td>1/16</td>
</tr>
<tr>
<td>9</td>
<td>Deteriorated</td>
<td>1</td>
<td>&lt;1/16</td>
<td>1/64</td>
<td>1/16</td>
</tr>
<tr>
<td>10</td>
<td>Deteriorated</td>
<td>1</td>
<td>1/32</td>
<td>1/32</td>
<td>1/16</td>
</tr>
<tr>
<td>11</td>
<td>Deteriorated</td>
<td>2</td>
<td>1/32</td>
<td>1/32</td>
<td>1/16</td>
</tr>
<tr>
<td>12</td>
<td>Deteriorated</td>
<td>1</td>
<td>1/32</td>
<td>1/32</td>
<td>&lt;1/16</td>
</tr>
<tr>
<td>13</td>
<td>Deteriorated</td>
<td>6</td>
<td>1/32</td>
<td>1/32</td>
<td>1/16</td>
</tr>
<tr>
<td>14</td>
<td>Stable</td>
<td>6</td>
<td>1/32</td>
<td>1/32</td>
<td>&lt;1/16</td>
</tr>
</tbody>
</table>

Table 3  Results of sequential Legionella pneumophila antibody tests in patients with cystic fibrosis who did not have antibody demonstrable at ≥1/32 (indirect fluorescent antibody test)

<table>
<thead>
<tr>
<th>Antibody titre</th>
<th>At initial visit</th>
<th>1 m later</th>
<th>1 y later</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1/16</td>
<td>&lt;1/16</td>
<td>&lt;1/16</td>
<td>13</td>
</tr>
<tr>
<td>1/16</td>
<td>&lt;1/16</td>
<td>&lt;1/16</td>
<td>3</td>
</tr>
<tr>
<td>1/16</td>
<td>1/16</td>
<td>&lt;1/16</td>
<td>1</td>
</tr>
<tr>
<td>1/16</td>
<td>1/16</td>
<td>1/16</td>
<td>2</td>
</tr>
<tr>
<td>&lt;1/16</td>
<td>1/16</td>
<td>&lt;1/16</td>
<td>1</td>
</tr>
</tbody>
</table>

No Group Patient
Viruses and *Legionella pneumophila* in respiratory exacerbations in cystic fibrosis

Table 4  Principal bacterial pathogens in sputum of patients from the different groups at the initial visit

<table>
<thead>
<tr>
<th>Principal bacterium</th>
<th>Stable group (n = 22)</th>
<th>Deteriorated group (n = 24)</th>
<th>Deteriorated group with non-bacterial infection (n = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>17 (77.3)</td>
<td>20 (83.3)</td>
<td>5 (71.4)</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>2 (9.1)</td>
<td>2 (8.3)</td>
<td>1 (14.3)</td>
</tr>
<tr>
<td><em>Staphylococcus pyogenes</em></td>
<td>2 (9.1)</td>
<td>1 (4.2)</td>
<td>1 (14.3)</td>
</tr>
</tbody>
</table>

There was no significant difference between the different groups (χ² test).

This study. Other types of antigen have produced false positive results with adenovirus¹² and mycoplasma¹⁶ infections in the past. This incidence of 17.4% with demonstrable titres of *L pneumophila* antibody in our study contrasts significantly with 3.4% in a population of 502 randomly selected blood donors¹⁴ and with 3.8% in a group of 1378 patients with respiratory illness not due to legionnaires' disease.¹⁷ In at least three of the eight patients with antibody titres of 1/32 or more infection with *L pneumophila* was strongly suggested. In one of these the antibody titres rose from less than 1/16 to 1/64 during the study and were accompanied by a respiratory illness responsive to treatment with erythromycin. We believe that this is the first time an *L pneumophila* infection has been confirmed in a patient with cystic fibrosis. Two other patients in whom the *L pneumophila* antibody titres showed a fourfold reduction, from 1/128 one year before the present study to < 1/16 at the end of the study, had both had a respiratory illness consistent with legionnaires' disease. These two patients may have been recovering from *L pneumophila* infection between the pilot study and the present one.

Immunosuppressants, including corticosteroids, are thought to be predisposing factors in legionnaires' disease¹⁸¹⁹ but they did not explain the high incidence of demonstrable *L pneumophila* antibody titres in our patients. In a study of 41 patients with asthma 20% had raised titres of antibody against *L pneumophila*.¹⁹ There appeared to be no relationship between the presence of raised antibody titres and corticosteroid treatment.

Possibly therefore there is a higher incidence of infection with *L pneumophila* in patients with cystic fibrosis than in healthy controls. Alternative explanations for the demonstrable *L pneumophila* antibody titres might include overactivity of the immune system, reflected by raised immunoglobulin concentrations,²⁰ an increased prevalence of *Aspergillus fumigatus* precipitins,²¹ or simply an anamnestic response. Serological cross reactivity between *L pneumophila* and *P aeruginosa* has been recorded (M Collins et al, paper presented to the 11th Euro-
impaired immunological defences, or simply to increased exposure.

Bacteria, notably *P. aeruginosa*, are the main pathogens in patients with cystic fibrosis. Viral, mycoplasma, coxiella, and legionella infections, however, may be associated with up to a third of the acute exacerbations of respiratory disease in young adults with cystic fibrosis. These organisms, in addition to the usual bacteria, should be sought and treatment instituted where appropriate.

We would like to thank Miss M Rehahn for help with statistical analysis and Miss S Hockley for typing the manuscript.

References

Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis.
J Efthimiou, M E Hodson, P Taylor, A G Taylor and J C Batten

Thorax 1984 39: 150-154
doi: 10.1136/thx.39.2.150

Updated information and services can be found at:
http://thorax.bmj.com/content/39/2/150

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/